Ameriprise
GSK icon

Ameriprise’s GSK GSK Stock Holding History

Ameriprise’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.1M Buy
381,099
+80,716
+27% +$4.37M ﹤0.01% 1374
2025
Q4 		$14.7M Sell
300,383
-6,923
-2% -$323K ﹤0.01% 1637
2025
Q3 		$13.3M Sell
307,306
-94,471
-24% -$3.69M ﹤0.01% 1701
2025
Q2 		$15.4M Buy
401,777
+4,855
+1% +$186K ﹤0.01% 1508
2025
Q1 		$15.4M Sell
396,922
-81,818
-17% -$3M ﹤0.01% 1482
2024
Q4 		$16.2M Sell
478,740
-52,224
-10% -$1.88M ﹤0.01% 1479
2024
Q3 		$21.7M Sell
530,964
-75,736
-12% -$3.1M 0.01% 1285
2024
Q2 		$23.4M Buy
606,700
+66,202
+12% +$2.78M 0.01% 1183
2024
Q1 		$23.2M Sell
540,498
-75,618
-12% -$3.12M 0.01% 1219
2023
Q4 		$22.8M Sell
616,116
-654,666
-52% -$23.5M 0.01% 1191
2023
Q3 		$46.1M Buy
1,270,782
+43,753
+4% +$1.55M 0.02% 787
2023
Q2 		$43.7M Buy
1,227,029
+189,552
+18% +$6.8M 0.01% 819
2023
Q1 		$36.9M Buy
1,037,477
+148,672
+17% +$5.2M 0.01% 902
2022
Q4 		$31.2M Buy
888,805
+65,946
+8% +$2.2M 0.01% 963
2022
Q3 		$24.1M Sell
822,859
-209,228
-20% -$7.93M 0.01% 1069
2022
Q2 		$56.2M Buy
1,032,087
+60,585
+6% +$3.34M 0.02% 672
2022
Q1 		$52.9M Buy
971,502
+247,553
+34% +$13.4M 0.02% 784
2021
Q4 		$40M Buy
723,949
+120,544
+20% +$6.27M 0.01% 949
2021
Q3 		$28.8M Sell
603,405
-200,359
-25% -$10.1M 0.01% 1028
2021
Q2 		$40.1M Sell
803,764
-562,670
-41% -$27M 0.01% 905
2021
Q1 		$63.1M Sell
1,366,434
-367,460
-21% -$16.7M 0.02% 676
2020
Q4 		$79.6M Sell
1,733,894
-685,535
-28% -$31.5M 0.03% 551
2020
Q3 		$115M Sell
2,419,429
-202,641
-8% -$10.2M 0.05% 388
2020
Q2 		$133M Sell
2,622,070
-131,407
-5% -$6.74M 0.06% 322
2020
Q1 		$132M Buy
2,753,477
+380,720
+16% +$20.3M 0.07% 272
2019
Q4 		$140M Buy
2,372,757
+126,391
+6% +$7.03M 0.06% 315
2019
Q3 		$120M Buy
2,246,366
+1,189,723
+113% +$61.2M 0.05% 345
2019
Q2 		$52.1M Buy
1,056,643
+37,992
+4% +$1.91M 0.02% 657
2019
Q1 		$53.2M Buy
1,018,651
+245,292
+32% +$12.3M 0.02% 622
2018
Q4 		$37M Buy
773,359
+15,017
+2% +$740K 0.02% 741
2018
Q3 		$41.4M Buy
758,342
+42,154
+6% +$2.14M 0.01% 844
2018
Q2 		$36.1M Sell
716,188
-27,991
-4% -$1.41M 0.02% 822
2018
Q1 		$36.4M Sell
744,179
-610,815
-45% -$28.4M 0.02% 804
2017
Q4 		$60.1M Sell
1,354,994
-129,120
-9% -$5.96M 0.03% 517
2017
Q3 		$75M Buy
1,484,114
+98,108
+7% +$4.98M 0.04% 443
2017
Q2 		$74.8M Sell
1,386,006
-1,584,418
-53% -$84.5M 0.04% 439
2017
Q1 		$158M Sell
2,970,424
-166,774
-5% -$8.46M 0.08% 257
2016
Q4 		$150M Buy
3,137,198
+324,038
+12% +$16M 0.08% 253
2016
Q3 		$152M Buy
2,813,160
+382,653
+16% +$21M 0.09% 232
2016
Q2 		$133M Buy
2,430,507
+482,154
+25% +$25.4M 0.08% 250
2016
Q1 		$98.5M Buy
1,948,353
+447,314
+30% +$22.3M 0.06% 309
2015
Q4 		$75.8M Buy
1,501,039
+119,765
+9% +$6.1M 0.04% 364
2015
Q3 		$66.4M Buy
1,381,274
+240,750
+21% +$12.5M 0.04% 387
2015
Q2 		$59.1M Buy
1,140,524
+35,218
+3% +$1.98M 0.03% 459
2015
Q1 		$63.8M Buy
1,105,306
+302,742
+38% +$17.4M 0.04% 449
2014
Q4 		$42.9M Buy
802,564
+29,695
+4% +$1.66M 0.03% 570
2014
Q3 		$44.4M Buy
772,869
+63,134
+9% +$3.87M 0.03% 555
2014
Q2 		$47.5M Buy
709,735
+32,797
+5% +$2.22M 0.03% 560
2014
Q1 		$45.2M Sell
676,938
-2,045,591
-75% -$138M 0.03% 579
2013
Q4 		$182M Sell
2,722,529
-16,381
-0.6% -$1.06M 0.11% 216
2013
Q3 		$172M Buy
2,738,910
+102,500
+4% +$6.6M 0.11% 202
2013
Q2 		$165M Buy
+2,636,410
New +$167M 0.11% 207

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Ameriprise's GSK Position: Q1 2026 in Review

Ameriprise increased its GSK (GSK) stake by 27% in Q1 2026, buying an estimated $4.37M and bringing the position to 381,099 shares worth $21.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1374.

Ameriprise first reported a position in GSK in Q2 2013 and has held it in 52 quarters since. The position peaked at $182M in Q4 2013. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Ameriprise held 381,099 shares of GSK worth $21.1M as of Q1 2026.
  • Ameriprise bought 80,716 GSK shares in Q1 2026, an estimated $4.37M.
  • GSK made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #1374 holding.
  • Ameriprise first reported a position in GSK in Q2 2013 and has held it in 52 quarters since.
  • Ameriprise's GSK position peaked at $182M in Q4 2013.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.